Literature DB >> 7618941

Increased generation of cysteinyl leukotrienes in Kawasaki disease.

E Mayatepek1, W D Lehmann.   

Abstract

Endogenous cysteinyl leukotriene synthesis was assessed in 10 patients with Kawasaki disease and 10 healthy controls by measuring excretion of leukotriene E4 (LTE4) in urine. LTE4 was increased more than fivefold in patients with Kawasaki disease compared with controls (median (range) 55.3 (31.8-120.6) v 10.2 (7.1-14.9) nmol/mol creatinine); this suggests that cysteinyl leukotrienes are involved in the pathophysiology of Kawasaki disease. Leukotriene synthetase inhibition or receptor antagonism may therefore offer a new potential therapeutic approach in children with this disease.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7618941      PMCID: PMC1511137          DOI: 10.1136/adc.72.6.526

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  7 in total

1.  Increased in vitro leukotriene B4 production by stimulated polymorphonuclear cells in Kawasaki disease.

Authors:  Y Hamasaki; T Ichimaru; H Koga; H Tasaki; S Miyazaki
Journal:  Acta Paediatr Jpn       Date:  1989-06

2.  Kawasaki disease: cardiac problems and management.

Authors:  H Kato; O Inoue; T Akagi
Journal:  Pediatr Rev       Date:  1988-01

Review 3.  Leukotrienes: biosynthesis, metabolism, and pathophysiologic significance.

Authors:  E Mayatepek; G F Hoffmann
Journal:  Pediatr Res       Date:  1995-01       Impact factor: 3.756

4.  Increased synthesis of thromboxane A2 by platelets from patients with Kawasaki disease.

Authors:  T Hidaka; M Nakano; T Ueta; Y Komatsu; M Yamamoto
Journal:  J Pediatr       Date:  1983-01       Impact factor: 4.406

5.  A new infantile acute febrile mucocutaneous lymph node syndrome (MLNS) prevailing in Japan.

Authors:  T Kawasaki; F Kosaki; S Okawa; I Shigematsu; H Yanagawa
Journal:  Pediatrics       Date:  1974-09       Impact factor: 7.124

6.  Impaired degradation of leukotrienes in patients with peroxisome deficiency disorders.

Authors:  E Mayatepek; W D Lehmann; J Fauler; D Tsikas; J C Frölich; R B Schutgens; R J Wanders; D Keppler
Journal:  J Clin Invest       Date:  1993-03       Impact factor: 14.808

7.  Increased urinary leukotriene excretion in patients with cardiac ischemia. In vivo evidence for 5-lipoxygenase activation.

Authors:  M Carry; V Korley; J T Willerson; L Weigelt; A W Ford-Hutchinson; P Tagari
Journal:  Circulation       Date:  1992-01       Impact factor: 29.690

  7 in total
  4 in total

Review 1.  The measurement of leukotrienes in human fluids.

Authors:  J Y Westcott
Journal:  Clin Rev Allergy Immunol       Date:  1999 Spring-Summer       Impact factor: 8.667

2.  Aspirin treatment and increased generation of cysteinyl leukotrienes in Kawasaki disease.

Authors:  T Shimizu; Y Yamashiro; K Yabuta
Journal:  Arch Dis Child       Date:  1996-01       Impact factor: 3.791

3.  Urinary Colorimetric Sensor Array and Algorithm to Distinguish Kawasaki Disease from Other Febrile Illnesses.

Authors:  Zhen Li; Zhou Tan; Shiying Hao; Bo Jin; Xiaohong Deng; Guang Hu; Xiaodan Liu; Jie Zhang; Hua Jin; Min Huang; John T Kanegaye; Adriana H Tremoulet; Jane C Burns; Jianmin Wu; Harvey J Cohen; Xuefeng B Ling
Journal:  PLoS One       Date:  2016-02-09       Impact factor: 3.240

Review 4.  Kawasaki Disease and Allergic Diseases.

Authors:  Po-Yu Huang; Ying-Hsien Huang; Mindy Ming-Huey Guo; Ling-Sai Chang; Ho-Chang Kuo
Journal:  Front Pediatr       Date:  2021-01-07       Impact factor: 3.418

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.